Compare GoPro Inc (GPRO) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GoPro Inc vs ResMed Inc. — how do they compare? GoPro Inc trades at $0.67 (market cap $122.03M), while ResMed Inc. trades at $200.8 (market cap $28.80B). The key difference: ResMed Inc. is far larger — about 236× GoPro Inc's market cap, and ResMed Inc. pays a 1.21% dividend while GoPro Inc pays none. Which is the better fit depends on your goals.
| GPRO | RMD | |
|---|---|---|
Market Cap | $122.03M | $28.80B |
Sector | Technology | Health |
52-Week High | $2.88 | $293.73 |
52-Week Low | $0.64 | $182.82 |
Enterprise Value | $169.98M | $27.99B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoPro (GPRO) trades at $0.6732, down 3.53% on the day, reflecting persistent financial stress with a net income margin of -20.7% and negative cash flow. The company is undergoing a strategic review for potential sale or merger, announced May 11, 2026, after receiving inbound interest. Technical indicators are bearish, with moving averages signaling continued downward pressure, while recent product launches like the MISSION 1 series aim to revive growth amid declining revenues.
The outlook hinges on the strategic review outcome; a successful sale could provide shareholder value, but ongoing losses and high burn rate pose significant risks. Investors face binary event-driven speculation, with analyst consensus mixed and substantial downside if restructuring fails.
ResMed (RMD) trades at $196.37, up 1.74% with strong fundamental performance including 27.44% net margins and consistent earnings beats. The company recently sold its MatrixCare business for $490 million to sharpen focus on core sleep and respiratory care markets. Technical indicators show bearish momentum despite oversold RSI conditions, while fundamentals demonstrate robust revenue growth from $5.15B to projected $5.5B in 2026.
RMD presents a compelling growth story with 40% analyst buy ratings and $245.88 consensus target suggesting 25% upside. Key risks include competitive pressures in medical technology and execution of strategic refocusing. The stock's current valuation at 19.15 P/E appears reasonable given earnings momentum and market leadership in sleep apnea treatment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
